| アブストラクト | BACKGROUND/AIMS: We assessed the survival benefit of polymyxin B hemoperfusion (PMX) in septic shock patients starting continuous renal replacement therapy (CRRT), who are known to have an increased rate of mortality. METHODS: Adult patients in the Japanese diagnosis procedure combination database satisfying the following criteria were enrolled: hospitalized in 2007-2012; diagnosed as having sepsis; required noradrenaline and/or dopamine; and started CRRT in intensive care unit. Propensity scores for receiving PMX were created from patient and hospital characteristics. RESULTS: Of 3,759 eligible patients, 1,068 received PMX. Propensity-score matching produced a matched cohort of 978 pairs. The 28-day mortality was 40.2% (393/978) in the PMX group and 46.8% (458/978) in the control group (p = 0.003). Logistic regression analysis revealed a significant association between the use of PMX and decreased 28-day mortality (adjusted OR 0.75; 95% CI 0.62-0.91). CONCLUSION: This large retrospective study suggests that septic shock patients starting CRRT may benefit from PMX. |
|---|
| ジャーナル名 | Blood purification |
|---|
| Pubmed追加日 | 2016/2/27 |
|---|
| 投稿者 | Iwagami, Masao; Yasunaga, Hideo; Noiri, Eisei; Horiguchi, Hiromasa; Fushimi, Kiyohide; Matsubara, Takehiro; Yahagi, Naoki; Nangaku, Masaomi; Doi, Kent |
|---|
| 組織名 | Department of Hemodialysis and Apheresis, School of Public Health, The University;of Tokyo Hospital, Tokyo, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/26918904/ |
|---|
